If your insurance stopped covering Wegovy®, you generally have four paths: appeal the denial or ask about a formulary exception, pay cash for Wegovy® directly (including, for some patients, Novo Nordisk's own NovoCare self-pay program), ask your clinician whether a different FDA-approved GLP-1 fits your plan's coverage, or ask about compounded semaglutide as a separate, non-equivalent option. None of these guarantee a specific outcome — a US-licensed clinician reviews your history and guides which path, if any, makes sense for you.
The short answer
Losing Wegovy® coverage doesn't mean losing access to treatment. Your options are: appeal the insurance decision, pay cash (Wegovy® directly or through NovoCare), ask about switching to a different FDA-approved GLP-1, or ask your clinician about compounded semaglutide as a separate §503A option. Eligibility for any path is determined by a US-licensed clinician.
Why did my insurance stop covering Wegovy®?
A handful of common reasons, and none of them mean you did anything wrong:
- Formulary changes. Insurers revise their covered-drug lists annually (sometimes mid-year), and anti-obesity medications are a frequent target given their cost to the plan.
- Employer opt-out. Many employer-sponsored plans specifically exclude weight-loss medications, even when the same insurer covers Wegovy® for other employer groups.
- New prior-authorization criteria. A plan may keep covering Wegovy® but add requirements — a minimum BMI, documentation of a supervised diet attempt, or periodic re-authorization — that your existing prescription didn't meet.
- Medicare's statutory exclusion. Medicare is prohibited by law from covering medications prescribed for weight loss, so Medicare does not cover Wegovy® regardless of diagnosis or plan.
What are my options, step by step?
| Option | What it involves | Paid via | Note |
|---|---|---|---|
| Appeal or request a formulary exception | Your clinician submits documentation supporting medical necessity | Insurance, if approved | Can take days to weeks; not guaranteed |
| Pay cash for Wegovy® | Direct cash payment, including Novo Nordisk's own NovoCare self-pay channel for eligible patients | Cash-pay | Same FDA-approved product either way |
| Ask about a different FDA-approved GLP-1 | Your clinician reviews whether Zepbound®, Mounjaro®, or (for a type 2 diabetes diagnosis) Ozempic® fits your plan and history | Insurance or cash, depending on coverage | A clinical decision, not a guarantee your plan covers the alternative |
| Ask about compounded semaglutide | A separate §503A option your clinician may consider, documented with a patient-specific clinical rationale | Cash-pay | Not FDA-approved; not a substitute for Wegovy® — see below |
See what's appropriate for you
A US-licensed clinician reviews your history and current coverage situation and discusses which option, if any, fits.
Start your intake →Can I appeal an insurance denial for Wegovy®?
Often, yes — appeals succeed more often than patients expect, especially when the denial is about prior-authorization paperwork rather than a flat plan exclusion. A few steps that help:
- Get the denial reason in writing. Insurers are required to state why a claim or prior authorization was denied; the reason determines what kind of appeal makes sense.
- Ask your clinician for a letter of medical necessity. This documents your diagnosis, prior treatment history, and clinical rationale for Wegovy® specifically.
- Follow your plan's formal appeal process. Every plan has one, usually with a specific deadline and a required form — your insurer's member portal or the denial letter itself will list the steps.
- Check whether new criteria apply. If the plan added requirements (a BMI threshold, documented diet history, a step-therapy requirement), find out whether you already meet them — sometimes it's a documentation gap, not a true denial.
If a plan excludes weight-loss medications entirely, an appeal on medical-necessity grounds is unlikely to succeed — that's a coverage-design decision, not a clinical judgment call.
What does Wegovy® cost with cash pay?
Two cash-pay paths exist for the same FDA-approved product:
Through a standard pharmacy or a telehealth platform, cash-pay Wegovy® pricing varies by pharmacy — at Pallas it's $1,349/mo cash-pay, not billed to insurance. Through NovoCare, Novo Nordisk's own self-pay channel, eligible self-pay patients may find a lower-cost path directly from the manufacturer; this article intentionally doesn't quote NovoCare's pricing, since self-pay rates change — see NovoCare directly or our semaglutide cost breakdown for current figures. Either way, the medication itself is the same FDA-approved product — the payment channel changes, not the drug.
Could a different FDA-approved GLP-1 work instead?
Possibly — that's a clinical decision your provider makes with you, not something to decide from a formulary PDF alone. A few things worth knowing:
- Zepbound® and Mounjaro® (tirzepatide, Eli Lilly) are a different molecule from Wegovy®/Ozempic® (semaglutide, Novo Nordisk), approved separately, and may sit on a different formulary tier with your specific plan. See our Wegovy® vs. Zepbound® comparison and semaglutide vs. tirzepatide comparison for how the two differ.
- Ozempic® (also semaglutide) is FDA-approved specifically for type 2 diabetes, not weight management on its own — a clinician would only consider it if that's your diagnosis.
- Switching brands doesn't reset your coverage odds automatically. Some plans exclude the entire anti-obesity drug class regardless of which specific medication you request.
Talk through your options with a clinician
A US-licensed provider can review your coverage situation, history, and goals and discuss which FDA-approved or compounded option, if any, fits.
Start your intake →Is compounded semaglutide an option if insurance won't cover Wegovy®?
It's a separate option a clinician may consider — not a substitute for Wegovy®, and not something a lost insurance claim by itself justifies. Compounded semaglutide is prepared per-patient by a US-licensed compounding pharmacy under FDCA §503A, and current FDA guidance requires a documented, patient-specific clinical rationale for that prescription — an intolerance to the FDA-approved formulation, a non-standard dose need, or another documented clinical reason. An insurance denial, price alone, or general preference for the compounded option isn't a sufficient basis on its own.
Compounded medications are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy. While these pharmacies are highly regulated, the compounded medications themselves are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary.
If your clinician determines a compounded preparation is appropriate for you for a documented clinical reason, it's dispensed as its own, separately regulated product — not framed as a like-for-like swap for Wegovy®. For a full breakdown of how the two differ, see compounded vs. brand-name GLP-1 medications and how much compounded semaglutide costs.
Where does Pallas fit?
Pallas dispenses FDA-approved Wegovy® through US-licensed pharmacies on a cash-pay basis, and separately offers compounded semaglutide, prepared by US-licensed compounding pharmacies, when a clinician documents it's the appropriate option for you. Both are cash-pay; insurance isn't billed for either. A licensed partner pharmacy fills and ships whichever prescription your clinician writes, and eligibility for any option is always determined by a US-licensed clinician. Learn more about semaglutide treatment at Pallas.
Frequently asked questions
Four main paths: appeal the denial or ask about a formulary exception, pay cash for Wegovy® directly (including, for some patients, Novo Nordisk's own NovoCare self-pay channel), ask your clinician whether a different FDA-approved GLP-1 fits your plan, or ask about compounded semaglutide as a separate, non-equivalent §503A option. A US-licensed clinician reviews your history and current coverage situation to help you decide which, if any, is right for you.
The same four paths apply regardless of how the coverage loss happened — a formulary change, an employer opt-out, or a denied prior authorization: appeal, pay cash (directly or through NovoCare), ask about a different FDA-approved GLP-1, or ask about compounded semaglutide as a separate option your clinician may consider.
Often, yes, especially when the denial is about prior-authorization paperwork rather than a flat plan exclusion. Get the denial reason in writing, ask your clinician for a letter of medical necessity, and follow your plan's formal appeal process and deadline. If your plan excludes weight-loss medications as a category, a medical-necessity appeal is unlikely to succeed — that's a coverage-design decision, not a clinical one.
It can. NovoCare is Novo Nordisk's own self-pay channel, and it's a legitimate source since it's operated by the manufacturer — it can be a lower-cost way for eligible self-pay patients to get genuine Wegovy®. Check NovoCare directly for current pricing and eligibility.
That's a decision for your clinician, not something an insurance denial decides on its own. Compounded semaglutide is prepared per-patient by a US-licensed compounding pharmacy under FDCA §503A, and current FDA guidance requires a documented, patient-specific clinical rationale for that prescription — an insurance denial or price alone isn't a sufficient basis. It is not FDA-approved, not a generic version of Wegovy®, and has not been evaluated by the FDA for safety, efficacy, or quality.
No. Zepbound® and Mounjaro® (tirzepatide, Eli Lilly) are a different molecule from Wegovy®/Ozempic® (semaglutide, Novo Nordisk) and may sit on a different formulary tier with your specific plan, but some plans exclude the entire anti-obesity drug class regardless of which specific medication is prescribed. Whether an alternative is clinically appropriate — and whether your plan covers it — are two separate questions your clinician and your insurer each answer.
References
- U.S. Food and Drug Administration. WEGOVY® (semaglutide) prescribing information. 2026.
- U.S. Food and Drug Administration. FDA's Concerns With Unapproved GLP-1 Drugs Used for Weight Loss. 2026.
- U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. 2026.
Bottom line: A dropped or denied Wegovy® claim isn't a dead end. Appealing the decision, paying cash (directly or through NovoCare), asking about a different FDA-approved GLP-1, and asking about compounded semaglutide as a separate §503A option are all real paths — none of them guaranteed, and all of them starting with a clinician who reviews your specific history and current coverage.
See what's appropriate for you
Complete a short health questionnaire, and a US-licensed clinician will review your history and discuss which option fits — no insurance needed, no membership fee.
Start your intake →Trademarks & disclosures
Wegovy® and Ozempic® are registered trademarks of Novo Nordisk. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. Pallas is not affiliated with, endorsed by, or sponsored by either manufacturer. Brand-name GLP-1 medications dispensed through Pallas are cash-pay only and are not billed to insurance. Prescriptions — brand-name or compounded — are written only when a US-licensed clinician determines treatment is appropriate.